Drupal.behaviors.print = function(context) {window.print();window.close();}>
Healthlinx's OvPlex Deal with Mane Cancer Dx Expires as Mane Unable to Raise Needed Funds
January 11, 2013
Healthlinx's OvPlex Deal with Mane Cancer Dx Expires as Mane Unable to Raise Needed Funds
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
Mane Cancer Dx Requests Extension of Deadlines Related to Healthlinx OvPlex Deal
December 7, 2012 / ProteoMonitor
Healthlinx Shareholders Approve Sale of OvPlex Dx to Mane Cancer Diagnostics
October 5, 2012 / ProteoMonitor
UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor
Healthlinx Inks Deal to Sell OvPlex Dx to San Diego-Based Startup Mane Cancer Diagnostics
August 31, 2012 / ProteoMonitor
HealthLinx Says New OvPlex Algorithm Beats CA125 in Avoiding False Positives
July 6, 2012 / ProteoMonitor